MedicalSystem Biotechnology Co

MedicalSystem Biotechnology Co Equity

The The Equity of MedicalSystem Biotechnology Co (300439.SZ) as of Nov 1, 2026 is 2.95 B CNY. In the previous year, The Equity was 2.94 B CNY — a change of 0.49% (higher).

Equity

2.95 BCNY

YoY

0.49%

Last updated:

In 2025, MedicalSystem Biotechnology Co's equity was 2.95 B CNY, a 0.49% increase from the 2.94 B CNY equity in the previous year.

The MedicalSystem Biotechnology Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
1.87 B CNY
Jan 1, 2019
1.34 B CNY
Jan 1, 2020
1.64 B CNY
Jan 1, 2021
2.35 B CNY
Jan 1, 2022
2.51 B CNY
Jan 1, 2023
2.71 B CNY
Jan 1, 2024
2.94 B CNY
Jan 1, 2025
2.95 B CNY
The MedicalSystem Biotechnology Co Equity history
YEAREquityYoY
2.95 BCNY+0.49%
2.94 BCNY+8.28%
2.71 BCNY+8.16%
2.51 BCNY+6.95%
2.35 BCNY+42.96%
1.64 BCNY+22.77%
1.34 BCNY-28.50%
1.87 BCNY-1.18%
1.89 BCNY+17.16%
1.62 BCNY+25.43%
1.29 BCNY+211.23%
413.83 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

MedicalSystem Biotechnology Co Stock analysis

What does MedicalSystem Biotechnology Co do? MedicalSystem Biotechnology Co., Ltd. generates revenue through the research, development, and manufacturing of bio-tech pharmaceutical products. The company sells in-vitro diagnostic reagents and instruments, along with third-party medical diagnosis services and reagent raw materials. Its primary market is the domestic Chinese market, serving healthcare providers and medical institutions that require diagnostic tools and services. The firm's product portfolio includes in-vitro diagnostic reagent, in-vitro diagnostic instrument, and reagent raw materials, all contributing to its revenue streams. The company focuses on the domestic market, where it provides in-vitro diagnostic products and services to hospitals and clinics. Its diagnostic reagents and instruments are used for medical testing, while the reagent raw materials support manufacturing processes. Third-party medical diagnosis services are offered to clients seeking external testing solutions. The domestic market segment represents the core customer base for MedicalSystem Biotechnology's offerings. MedicalSystem Biotechnology Co., Ltd. operates within the bio-tech pharmaceutical sector, with revenue derived from the sale of diagnostic products and services. The company's in-vitro diagnostic reagent and instrument sales form the backbone of its business, complemented by third-party medical diagnosis services and reagent raw materials distribution. Domestic healthcare institutions are the primary buyers of these products and services, driving the company's financial performance. MedicalSystem Biotechnology Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing MedicalSystem Biotechnology Co's Equity

MedicalSystem Biotechnology Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding MedicalSystem Biotechnology Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating MedicalSystem Biotechnology Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

MedicalSystem Biotechnology Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in MedicalSystem Biotechnology Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about MedicalSystem Biotechnology Co stock

The Equity of MedicalSystem Biotechnology Co is 2.95 B CNY in 2025.

The Equity of MedicalSystem Biotechnology Co changed from 2.94 B CNY to 2.95 B CNY, representing a 0.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity MedicalSystem Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's MedicalSystem Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — MedicalSystem Biotechnology Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — MedicalSystem Biotechnology Co